Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Assets (2016 - 2025)

Historic Assets for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $15.8 million.

  • China Pharma Holdings' Assets rose 1737.15% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year increase of 1737.15%. This contributed to the annual value of $14.9 million for FY2024, which is 960.38% down from last year.
  • As of Q3 2025, China Pharma Holdings' Assets stood at $15.8 million, which was up 1737.15% from $13.8 million recorded in Q2 2025.
  • China Pharma Holdings' Assets' 5-year high stood at $22.6 million during Q4 2021, with a 5-year trough of $13.5 million in Q3 2024.
  • Over the past 5 years, China Pharma Holdings' median Assets value was $16.2 million (recorded in 2022), while the average stood at $16.9 million.
  • In the last 5 years, China Pharma Holdings' Assets plummeted by 2148.2% in 2022 and then skyrocketed by 1737.15% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Assets stood at $22.6 million in 2021, then decreased by 21.48% to $17.8 million in 2022, then decreased by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then increased by 6.16% to $15.8 million in 2025.
  • Its last three reported values are $15.8 million in Q3 2025, $13.8 million for Q2 2025, and $14.2 million during Q1 2025.